Radionuclidic and Non-radionuclidic Molecular Imaging Agents for the Estrogen Receptor Based on 11-beta Subsituted Steroidal Anti-Estrogens
- Technology Benefits
- The technique:ΓÇóUtilizes novel steroidal derivatives as imaging agentsΓÇóAllows for an easier separation of unlabelled precursorsΓÇóIs based on high affinity anti-estrogen structure as compared to current estrogenic materialsΓÇóAllows for use of more stable and high affinity agents as compared to conventional techniquesΓÇóComprising the use of 11-beta substituted steroidal anti-estrogens as probes for ER selectivity and affinityΓÇóAllows for an easier detection of lesions in breast, ovaries, and uterus as compared to conventional techniquesΓÇóFurther allows for a reduced metabolism of agents as compared to conventional techniquesΓÇóIs modular in nature, comprising independent preparation of various components followed by incorporation using simple chemistries and physic-chemical diversitiesΓÇóWould be commercially useful for variety of applications such as PET, SPECT, Fluorescence, MRI and Raman especially for imaging at a cell, tissue, and a whole animal scale
- Detailed Technology Description
- None
- *Abstract
-
Currently, only few agents capable of noninvasive imaging for breast cancer are available. F-18 16 alpha-fluoro-estradiol (FES) is among the most common agents used in this regards. However, such agents are highly prone to in-vivo metabolism, are less stable, and are associated with higher liver update, and lower renal clearance. This approach discloses the development and use of a novel imaging technique comprising the use of novel agents to target estrogen receptors for visualization of tissues associated with variety of modalities.
- *Principal Investigator
-
Name: Kinh-Luan Dao
Department:
Name: Robert Hanson
Department:
- Country/Region
- USA
For more information, please click Here
